Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Development of a genotype 325-specific proCPU/TAFI ELISA.

Ann Gils1, Marie-Christine Alessi, Els Brouwers

  • 1Laboratory for Pharmaceutical Biology and Phytopharmacology, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, E. Van Evenstraat 4, B-3000 Leuven, Belgium. ann.gils@pharm.kuleuven.ac.be

Arteriosclerosis, Thrombosis, and Vascular Biology
|May 6, 2003
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel/Recurrent Variants in Pakistani Glanzmann Thrombasthenia and Glanzmann-like bleeding diathesis: Insights from NGS Analysis.

Thrombosis and haemostasis·2026
Same author

Circulating biomarkers of bronchoalveolar injury help predict the need for mechanical ventilation in patients with moderate to severe COVID-19 pneumonia: A prospective cohort study.

PloS one·2026
Same author

Natural history of antiplatelet antibody formation in patients with Glanzmann thrombasthenia: a French multicenter prospective study.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Platelet dense granule defect: experience in the French population.

Research and practice in thrombosis and haemostasis·2026
Same author

Motivational factors for general practice training and career establishment: A cross-sectional study in Flanders, Belgium.

The European journal of general practice·2026
Same author

Selection and optimization strategy for Rap1-targeting single-domain antibodies as platelet activation markers.

Research and practice in thrombosis and haemostasis·2026

New monoclonal antibodies accurately measure proprotein convertase subtilisin/kexin type 9 (PCSK9) levels, independent of the Thr/Ile 325 genotype. This improves diagnostic accuracy for cardiovascular risk markers.

Area of Science:

  • Biochemistry
  • Immunology
  • Cardiovascular Science

Background:

  • A Thr/Ile polymorphism at position 325 in proprotein convertase subtilisin/kexin type 9 (PCSK9) is known.
  • Accurate quantification of PCSK9 levels requires fully characterized immunological assays, considering genotype dependency.

Purpose of the Study:

  • To develop and characterize monoclonal antibodies for reliable measurement of plasma PCSK9.
  • To assess the genotype dependency of newly developed and commercially available PCSK9 assays.

Main Methods:

  • Generation of monoclonal antibodies against human plasma-derived PCSK9.
  • Selection of antibody pairs for PCSK9 quantification in plasma.
  • Evaluation of genotype dependency of PCSK9 assays using different genotypes (Ile/Ile, Ile/Thr, Thr/Thr).

Related Experiment Videos

Main Results:

  • Two antibody combinations, T12D11/T28G6-HRP and T32F6/T9G12-HRP, were selected for PCSK9 measurement.
  • T12D11/T28G6-HRP showed genotype independence, yielding 10.1+/-3.1 microg/mL in normal donors (n=86).
  • T32F6/T9G12-HRP demonstrated genotype dependency, with reactivity varying across genotypes and no reactivity with Ile/Ile.
  • Commercially available assays showed partial genotype dependency.

Conclusions:

  • Careful evaluation of PCSK9 antigen values is crucial.
  • PCSK9 levels should be interpreted cautiously as a causative agent or diagnostic risk marker for cardiovascular events due to potential genotype influences on assays.